Targeted disruption of the JAK2/STAT3 pathway in combination with systemic administration of paclitaxel inhibits the priming of ovarian cancer stem cells leading to a reduced tumor burden

Frontiers in Oncology

Volumn 4 APR, Issue , 2014, Pages

  Abubaker, Khalid ^a,b   Luwor, Rodney B ^b   Escalona, Ruth ^a   McNally, Orla ^a,b   Quinn, Michael A ^a,b   Thompson, Erik W ^b,c   Findlay, Jock K ^a,b,d   Ahmed, Nuzhat ^a,b,d  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Cancer stem cells; Chemoresistance; JAK2 STAT3 pathway; Metastasis; Ovarian carcinoma; Recurrence

Indexed keywords

CA 125 ANTIGEN; CD34 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; GELATINASE A; GELATINASE B; GLYCOPROTEIN GP 130; INTERLEUKIN 6; JANUS KINASE 2; KI 67 ANTIGEN; MOMELOTINIB; OCTAMER TRANSCRIPTION FACTOR 4; PACLITAXEL; STAT3 PROTEIN; STEM CELL FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER STEM CELL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; OVARY CANCER; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TUMOR VOLUME;

EID: 84901014050     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00075     Document Type: Article

References (46)

1. Ozols RF. Challenges for chemotherapy in ovarian cancer. Ann Oncol (2006) 17(Suppl 5):v181-7. doi:10.1093/annonc/mdj978.
2. Gabra H. Back to the future: targeting molecular changes for platinum resistance reversal. Gynecol Oncol (2010) 118(3):210-1. doi:10.1016/j.ygyno.2010.06.028.
3. Kipps E, Tan DS, Kaye SB. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer (2013) 13(4):273-82. doi:10.1038/nrc3432.
4. Jekunen AP, Christen RD, Shalinsky DR, Howell SB. Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. Br J Cancer (1994) 69(2):299-306. doi:10.1038/bjc.1994.55.
5. Aguilar-Gallardo C, Rutledge EC, Martinez-Arroyo AM, Hidalgo JJ, Domingo S, Simon C. Overcoming challenges of ovarian cancer stem cells: novel therapeutic approaches. Stem Cell Rev (2012) 8(3):994-1010. doi:10.1007/s12015-011-9344-5.
6. Ahmed N, Abubaker K, Findlay J, Quinn M. Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance. J Cell Biochem (2013) 114(1):21-34. doi:10.1002/jcb.24317.
7. Ahmed N, Abubaker K, Findlay JK. Ovarian cancer stem cells: molecular concepts and relevance as therapeutic targets. Mol Aspects Med (2013). doi:10.1016/j.mam.2013.06.002.
8. Alvero AB, Chen R, Fu HH, Montagna M, Schwartz PE, Rutherford T, et al. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle (2009) 8(1):158-66. doi:10.4161/cc.8.1.7533.
9. Latifi A, Luwor RB, Bilandzic M, Nazaretian S, Stenvers K, Pyman J, et al. Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors. PLoS One (2012) 7(10):e46858. doi:10.1371/journal.pone.0046858.
10. Steg AD, Bevis KS, Katre AA, Ziebarth A, Dobbin ZC, Alvarez RD, et al. Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin Cancer Res (2012) 18(3):869-81. doi:10.1158/1078-0432.CCR-11-2188.
11. Arwert EN, Hoste E, Watt FM. Epithelial stem cells, wound healing and cancer. Nat Rev Cancer (2012) 12(3):170-80. doi:10.1038/nrc3217.
12. Gatcliffe TA, Monk BJ, Planutis K, Holcombe RF. Wnt signaling in ovarian tumorigenesis. Int J Gynecol Cancer (2008) 18(5):954-62. doi:10.1111/j.1525-1438.2007.01127.x.
13. Kwon C, Cheng P, King IN, Andersen P, Shenje L, Nigam V, et al. Notch post-translationally regulates beta-catenin protein in stem and progenitor cells. Nat Cell Biol (2011) 13(10):1244-51. doi:10.1038/ncb2313.
14. Shodeinde AL, Barton BE. Potential use of STAT3 inhibitors in targeted prostate cancer therapy: future prospects. Onco Targets Ther (2012) 5:119-25. doi:10.2147/OTT.S32559.
15. Colomiere M, Ward AC, Riley C, Trenerry MK, Cameron-Smith D, Findlay J, et al. Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas. Br J Cancer (2009) 100(1):134-44. doi:10.1038/sj.bjc.6604794.
16. Ernst M, Putoczki TL. Stat3: linking inflammation to (gastrointestinal) tumourigenesis. Clin Exp Pharmacol Physiol (2011) 39(8):711-8. doi:10.1111/j.1440-1681.2011.05659.x.
17. Sansone P, Bromberg J. Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol (2012) 30(9):1005-14. doi:10.1200/JCO.2010.31.8907.
18. Wang X, Crowe PJ, Goldstein D, Yang JL. STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers (review). Int J Oncol (2012) 41(4):1181-91. doi:10.3892/ijo.2012.1568.
19. Groner B, Lucks P, Borghouts C. The function of Stat3 in tumor cells and their microenvironment. Semin Cell Dev Biol (2008) 19(4):341-50. doi:10.1016/j.semcdb.2008.06.005.
20. Song L, Turkson J, Karras JG, Jove R, Haura EB. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene (2003) 22(27):4150-65. doi:10.1038/sj.onc.1206479.
21. Kim DJ, Chan KS, Sano S, Digiovanni J. Signal transducer and activator of transcription 3 (Stat3) in epithelial carcinogenesis. Mol Carcinog (2007) 46(8):725-31. doi:10.1002/mc.20342.
22. Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melhem MF, Endo S, et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci U S A (2000) 97(8):4227-32. doi:10.1073/pnas.97.8.4227.
23. Sherry MM, Reeves A, Wu JK, Cochran BH. STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells (2009) 27(10):2383-92. doi:10.1002/stem.185.
24. Matthews JR, Sansom OJ, Clarke AR. Absolute requirement for STAT3 function in small-intestine crypt stem cell survival. Cell Death Differ (2011) 18(12):1934-43. doi:10.1038/cdd.2011.77.
25. Bourguignon LY, Peyrollier K, Xia W, Gilad E. Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem (2008) 283(25):17635-51. doi:10.1074/jbc.M800109200.
26. Ahmed N, Abubaker K, Findlay J, Quinn M. Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Curr Cancer Drug Targets (2010) 10(3):268-78. doi:10.2174/156800910791190175.
27. Duan Z, Foster R, Bell DA, Mahoney J, Wolak K, Vaidya A, et al. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin Cancer Res (2006) 12(17):5055-63. doi:10.1158/1078-0432.CCR-06-0861.
28. Costantino L, Barlocco D. STAT 3 as a target for cancer drug discovery. Curr Med Chem (2008) 15(9):834-43. doi:10.2174/092986708783955464.
29. Abubaker K, Latifi A, Luwor R, Nazaretian S, Zhu H, Quinn MA, et al. Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden. Mol Cancer (2013) 12(1):24. doi:10.1186/1476-4598-12-24.
30. Buick RN, Pullano R, Trent JM. Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res (1985) 45(8):3668-76.
31. Shield K, Riley C, Quinn MA, Rice GE, Ackland ML, Ahmed N. Alpha2beta1 integrin affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis. J Carcinog (2007) 6:11. doi:10.1186/1477-3163-6-11.
32. Yao HH-G, Aardenma J, Holthusen K. Sexually dimorphic regulation of inhibin beta B in establishing gonadal vasculature in mice. Biol Reprod (2006) 74:978-83. doi:10.1095/biolreprod.105.050286.
33. Luwor RB, Baradaran B, Taylor LE, Iaria J, Nheu TV, Amiry N, et al. Targeting Stat3 and Smad7 to restore TGF-beta cytostatic regulation of tumor cells in vitro and in vivo. Oncogene (2013) 32(19):2433-41. doi:10.1038/onc.2012.260.
34. Mofid B, Jalali Nodushan M, Rakhsha A, Zeinali L, Mirzaei H. Relation between HER-2 gene expression and Gleason score in patients with prostate cancer. Urol J (2007) 4(2):101-4.
35. Jennet M, Harvey GMC, Kent Osborne C, Craig Allred D. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol (1999) 17:1474-81.
36. Monaghan KA, Khong T, Burns CJ, Spencer A. The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells. Leukemia (2011) 25(12):1891-9. doi:10.1038/leu.2011.175.
37. Tyner JW, Bumm TG, Deininger J, Wood L, Aichberger KJ, Loriaux MM, et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood (2010) 115(25):5232-40. doi:10.1182/blood-2009-05-223727.
38. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A (2009) 106(33):13820-5. doi:10.1073/pnas.0905718106.
39. Todaro M, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, Iovino F, et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell (2007) 1(4):389-402. doi:10.1016/j.stem.2007.08.001.
40. Shaked Y, Henke E, Roodhart JM, Mancuso P, Langenberg MH, Colleoni M, et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell (2008) 14(3):263-73. doi:10.1016/j.ccr.2008.08.001.
41. Mackie AR, Losordo DW. CD34-positive stem cells: in the treatment of heart and vascular disease in human beings. Tex Heart Inst J (2011) 38(5):474-85.
42. Kawamoto A, Asahara T. Role of progenitor endothelial cells in cardiovascular disease and upcoming therapies. Catheter Cardiovasc Interv (2007) 70(4):477-84. doi:10.1002/ccd.21292.
43. Kumar J, Fraser FW, Riley C, Ahmed N, McCulloch DR, Ward AC. Granulocyte colony-stimulating factor receptor signalling via Janus kinase 2/signal transducer and activator of transcription 3 in ovarian cancer. Br J Cancer (2014) 110:133-45. doi:10.1038/bjc.2013.673.
44. Kulbe H, Chakravarty P, Leinster DA, Charles KA, Kwong J, Thompson RG, et al. A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Res (2012) 72(1):66-75. doi:10.1158/0008-5472.CAN-11-2178.
45. Kryczek I, Grybos M, Karabon L, Klimczak A, Lange A. IL-6 production in ovarian carcinoma is associated with histotype and biological characteristics of the tumour and influences local immunity. Br J Cancer (2000) 82(3):621-8. doi:10.1054/bjoc.1999.0973.
46. Wang Y, Niu XL, Qu Y, Wu J, Zhu YQ, Sun WJ, et al. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cancer Lett (2010) 295(1):110-23. doi:10.1016/j.canlet.2010.02.019.